Center for Novel Therapeutics in Addiction Psychiatry (NTAP) Joins ADAI!
02/02/2026
ADAI is pleased to announce that the UW Center for Novel Therapeutics in Addiction Psychiatry (NTAP) has joined our institute!
NTAP’s mission is to “create powerful news ways of treating people struggling with alcohol, opioid, tobacco, and other addictions by combining psychedelic compounds with evidence-based behavioral interventions.”
One of their current studies, for example, is investigating the use of psilocybin for alcohol use disorder and PTSD, examining its safety, effectiveness, and feasibility as a treatment for veterans and first responders. (This study is currently recruiting participants! Read more on the Psilostudy website.)
The center brings together experts with decades of experience across multiple disciplines and is led by Nathan Sackett, MD, MS.
ADAI is thrilled to be able to add NTAP and its staff and faculty to our team, and eager to learn more about the innovative use of psychedelics to help people struggling with addiction!
